Status:
RECRUITING
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Chronic Hepatitis B Virus (HBV) Infection
Eligibility:
All Genders
18+ years
Brief Summary
Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects aro...
Detailed Description
This study focuses on the chronic Hepatitis B virus (HBV) infection, which affects nearly 300 million people globally, leading to cirrhosis, hepatocellular carcinoma (HCC), and other severe liver dise...
Eligibility Criteria
Inclusion
- 18 years old
- Chronic HBV infection (HbsAg positive carrier for more than 6 months)
- Patient under care within the Henri Mondor-Albert Chenevier University Hospital group
Exclusion
- History of liver transplantation for liver failure in the context of chronic HBV infection
- Protected adults, adults unable to express their consent
- Pregnant or breastfeeding women
- Person not affiliated with a Social Security system
- Patient refusal to participate in the project
Key Trial Info
Start Date :
November 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 27 2038
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06906016
Start Date
November 28 2023
End Date
November 27 2038
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Unit (CRU) Henri Mondor.
Créteil, Créteil, France, 94000